The Pfizer-BioNTech vaccine showed 91.3% efficacy in a company-sponsored analysis of 927 confirmed symptomatic cases of COVID-19 after six months, an "important step" that could be enough for the vaccine to gain full approval from the U.S. Food and Drug Administration. | | News Alert Thursday, April 1 | | | | | | | |